These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23663281)

  • 21. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
    Singh SP; Singh V; Kar N
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):417-28. PubMed ID: 21859514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling the cost effectiveness of antidepressant treatment in primary care.
    Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
    Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
    Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does antidepressant step therapy fuel the law of unintended consequences?
    Greden JF
    Am J Psychiatry; 2010 Oct; 167(10):1148-51. PubMed ID: 20889657
    [No Abstract]   [Full Text] [Related]  

  • 27. Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.
    Solomon D; Adams J; Graves N
    J Affect Disord; 2013 Jun; 148(2-3):228-34. PubMed ID: 23291009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
    Machado M; Lopera MM; Diaz-Rojas J; Jaramillo LE; Einarson TR;
    Rev Panam Salud Publica; 2008 Oct; 24(4):233-9. PubMed ID: 19133171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost sharing and branded antidepressant initiation among patients treated with generics.
    Buxbaum JD; Chernew ME; Bonafede M; Vlahiotis A; Walter D; Mucha L; Fendrick AM
    Am J Manag Care; 2018 Apr; 24(4):180-186. PubMed ID: 29668208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
    Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA
    J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.
    Ramsberg J; Asseburg C; Henriksson M
    PLoS One; 2012; 7(8):e42003. PubMed ID: 22876296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review.
    Lee Y; Rosenblat JD; Lee J; Carmona NE; Subramaniapillai M; Shekotikhina M; Mansur RB; Brietzke E; Lee JH; Ho RC; Yim SJ; McIntyre RS
    J Affect Disord; 2018 Feb; 227():406-415. PubMed ID: 29154157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agomelatine for the treatment of major depressive disorder.
    Carney RM; Shelton RC
    Expert Opin Pharmacother; 2011 Oct; 12(15):2411-9. PubMed ID: 21916789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
    Fernandez JL; Montgomery S; Francois C
    Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.